Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
Alpha Tau Medical (Nasdaq: DRTS) announced changes to its Board of Directors, with Maya Netser joining and Meir Jakobsohn stepping down but continuing as an advisor. Netser brings over 25 years of experience as a C-level technology leader, board member, and investor. She is the founder of Quantum Leap VC and previously served as CEO of Cabaret Biotech, where she led the company to a successful acquisition by Kite Pharma and Gilead Sciences.
Netser's appointment comes at a strategic time as Alpha Tau expands into internal organ treatments with its Alpha DaRT® cancer therapy. She holds an LL.B and MBA from Tel Aviv University and is a member of the Israeli National Team of Directors.
Alpha Tau Medical (Nasdaq: DRTS) ha annunciato cambiamenti nel suo Consiglio di Amministrazione, con Maya Netser che si unisce e Meir Jakobsohn che si dimette, continuando però come consigliere. Netser porta con sé oltre 25 anni di esperienza come leader tecnologico a livello C, membro del consiglio e investitore. È la fondatrice di Quantum Leap VC e ha precedentemente ricoperto il ruolo di CEO di Cabaret Biotech, dove ha guidato l'azienda fino a una riuscita acquisizione da parte di Kite Pharma e Gilead Sciences.
L'appuntamento di Netser avviene in un momento strategico, poiché Alpha Tau si espande nei trattamenti degli organi interni con la sua terapia contro il cancro Alpha DaRT®. Possiede una laurea in giurisprudenza e un MBA dall'Università di Tel Aviv ed è membro della Nazionale israeliana dei Direttori.
Alpha Tau Medical (Nasdaq: DRTS) anunció cambios en su Junta Directiva, con Maya Netser uniéndose y Meir Jakobsohn dejando su puesto pero continuando como asesor. Netser aporta más de 25 años de experiencia como líder tecnológico a nivel C, miembro de la junta e inversor. Es fundadora de Quantum Leap VC y anteriormente fue CEO de Cabaret Biotech, donde llevó a la empresa a una exitosa adquisición por parte de Kite Pharma y Gilead Sciences.
El nombramiento de Netser llega en un momento estratégico, ya que Alpha Tau se expande en tratamientos de órganos internos con su terapia contra el cáncer Alpha DaRT®. Tiene un LL.B y un MBA de la Universidad de Tel Aviv y es miembro del Equipo Nacional de Directores de Israel.
알파 타우 메디컬 (Nasdaq: DRTS)는 이사회에 변화를 발표하며, 마야 네처가 합류하고 메이어 야콥손이 사임하지만 고문으로 계속 활동한다고 밝혔습니다. 네처는 25년 이상의 C급 기술 리더, 이사회 구성원 및 투자자로서의 경험을 가지고 있습니다. 그녀는 퀀텀 리프 VC의 창립자이며, 이전에는 카바레 바이오텍의 CEO로 재직하며 회사가 카이트 파마와 길리어드 사이언스에 성공적으로 인수되는 것을 이끌었습니다.
네처의 임명은 알파 타우가 알파 다RT® 암 치료법을 통해 내부 장기 치료로 확장하는 전략적 시점에 이루어집니다. 그녀는 텔아비브 대학교에서 법학 학위와 MBA를 취득하였으며, 이스라엘 국가 이사 팀의 일원입니다.
Alpha Tau Medical (Nasdaq: DRTS) a annoncé des changements dans son Conseil d'Administration, avec Maya Netser qui rejoint et Meir Jakobsohn qui démissionne tout en continuant comme conseiller. Netser apporte plus de 25 ans d'expérience en tant que leader technologique de niveau C, membre du conseil et investisseur. Elle est la fondatrice de Quantum Leap VC et a précédemment été PDG de Cabaret Biotech, où elle a dirigé l'entreprise vers une acquisition réussie par Kite Pharma et Gilead Sciences.
La nomination de Netser intervient à un moment stratégique alors qu'Alpha Tau se développe dans les traitements des organes internes avec sa thérapie contre le cancer Alpha DaRT®. Elle détient un LL.B et un MBA de l'Université de Tel Aviv et est membre de l'Équipe nationale israélienne des directeurs.
Alpha Tau Medical (Nasdaq: DRTS) hat Änderungen im Vorstand bekannt gegeben, wobei Maya Netser neu hinzukommt und Meir Jakobsohn zurücktritt, jedoch weiterhin als Berater tätig bleibt. Netser bringt über 25 Jahre Erfahrung als C-Level-Technologieführerin, Vorstandsmitglied und Investorin mit. Sie ist die Gründerin von Quantum Leap VC und war zuvor CEO von Cabaret Biotech, wo sie das Unternehmen zu einer erfolgreichen Akquisition durch Kite Pharma und Gilead Sciences führte.
Netsers Ernennung erfolgt zu einem strategischen Zeitpunkt, da Alpha Tau mit seiner Alpha DaRT®-Krebstherapie in die Behandlung innerer Organe expandiert. Sie verfügt über einen LL.B und MBA von der Universität Tel Aviv und ist Mitglied des israelischen Nationalteams der Direktoren.
- Strategic board appointment with extensive industry experience and successful track record in biotech exits
- Company expanding into treatment of internal organs, indicating product development progress
- Retention of departing board member as advisor maintains strategic continuity
- None.
JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company’s Board of Directors (“Board”). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity.
“I am delighted to welcome Maya to the Board,” said Company CEO and Chairman of the Board Mr. Uzi Sofer. “Maya brings a wealth of experience and a keen understanding of the industry from her many years of corporate leadership and advisory. She joins us as the Company is at an exciting strategic inflection point, undertaking a highly promising expansion into the treatment of internal organs. I am sure that Maya will be a wonderful partner in our mission to raise the standard of care for cancer patients worldwide.”
“I am so pleased to join Alpha Tau’s Board of Directors,” commented Ms. Netser. “I have been following the Company’s achievements with great interest and am eager to bring my life sciences and business development skills to help the Company continue to meet its extraordinary potential.”
Ms. Netser has over 25 years of experience as a C-level technology company leader, board member, investor, advisor, and law firm partner. Ms. Netser is the founder and Managing Partner of Quantum Leap VC, an early-stage fund focused on quantum technologies. Previously, Ms. Netser served as CEO of Cabaret Biotech, an Israeli CAR-T immunotherapy company based on Professor Zelig Eshhar’s pioneering inventions in cancer immunotherapy. Under her leadership, Cabaret successfully commercialized its IP, culminating in a high-profile acquisition by Kite Pharma and Gilead Sciences.
She previously served as COO and board member of Voyager Labs, an AI-based technology company that enables organizations to extract granular actionable insights from unstructured data. She was responsible for corporate business development, finance, human resources, legal, and investor relations.
Ms. Netser also has over 20 years of corporate and IP legal experience. From 2006-2015, she was a Partner at the law firm Herzog, Fox, and Neeman, where she established and led the firm’s technology practice, growing her team to 30 lawyers.
Ms. Netser holds an LL.B and an MBA from Tel Aviv University. She is also a member of the Israeli National Team of Directors.
In addition, the Company announced that Mr. Meir Jakobsohn has completed his term as a Board member but will continue to serve an advisory role to the Company.
“Meir has been a long-standing and deeply valued Board member who has contributed greatly to Alpha Tau’s success,” said Mr. Sofer. “I thank him for his many years of excellent service and I look forward to continuing to receive his wise counsel as a Company advisor.”
“Due to other commitments, I have decided not to seek re-election as a member of Alpha Tau’s Board,” Mr. Jakobsohn remarked. “It has been a privilege to have been a part of the Company’s extremely impressive growth from a small start-up to a public company with a highly advanced and sophisticated strategic pipeline. I wish Uzi and the Company the best of luck, and I am pleased to be able to stay connected with the Company as an advisor.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT ®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed; (v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with the SEC on March 7, 2024, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
FAQ
Who is Maya Netser and what experience does she bring to Alpha Tau Medical (DRTS)?
Why is Meir Jakobsohn leaving Alpha Tau Medical's (DRTS) board of directors?
What strategic developments is Alpha Tau Medical (DRTS) currently pursuing?
What is Maya Netser's role in Alpha Tau Medical's (DRTS) expansion strategy?
